Outcome of Deferred Initial Therapy in Mantle-Cell LymphomaPeter Martin, John P. Leonard, Amy Chadburn et al.|Journal of Clinical Oncology|2009Cited by 340
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell LymphomaJia Ruan, John P. Leonard, Ken Cheung et al.|Journal of Clinical Oncology|2010Cited by 319
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphomaJohn P. Leonard, Geoffrey I. Shapiro, Ann S. LaCasce et al.|Blood|2012Cited by 297
Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S <i>BTK</i> Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell LymphomaDavid Chiron, Selina Chen‐Kiang, Maurizio Di Liberto et al.|Cancer Discovery|2014Cited by 272
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapiesPeter Martin, John P. Leonard, Amy Chadburn et al.|Annals of Oncology|2008Cited by 76